Pfizer RSV Vaccine for Infants Has ‘Generally Favorable' Safety Data, FDA Staff Say

Australia News News

Pfizer RSV Vaccine for Infants Has ‘Generally Favorable' Safety Data, FDA Staff Say
Australia Latest News,Australia Headlines
  • 📰 NBCNewYork
  • ⏱ Reading Time:
  • 10 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 7%
  • Publisher: 63%

The FDA is slated to make a decision on whether to approve Pfizer’s shot in August before respiratory syncytial virus season in the fall

Pfizer's other RSV shotPfizer's RSV vaccine that protects infants is administered to expectant mothers in the late second or third trimester of their pregnancy.

Most of the more than 3,000 mothers who received the shot in a phase three trial experienced mild to moderate adverse reactions, according to the FDA staff's review of data.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

NBCNewYork /  🏆 270. in US

Australia Latest News, Australia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Sarepta stock soars 30% premarket after FDA panel backs accelerated approval for Duchenne muscular dystrophy therapySarepta stock soars 30% premarket after FDA panel backs accelerated approval for Duchenne muscular dystrophy therapySarepta Therapeutics Inc.’s stock soared 30% premarket Monday, after a U.S. Food and Drug Administration panel voted 8-6 in favor of accelerated approval for...
Read more »

FDA issues notice for recalled baby formula distributed out of NashvilleFDA issues notice for recalled baby formula distributed out of NashvilleRECALL: This recalled product was distributed from its Nashville Division only to independent retailers located in Alabama, Georgia, Indiana, Kentucky, Ohio, Tennessee, Virginia, and West Virginia.
Read more »

Sarepta surges after FDA panel backs Duchenne gene therapySarepta surges after FDA panel backs Duchenne gene therapyShares of Sarepta Therapeutics jumped 25% on Monday as a backing by the U.S. health regulator's advisers increased the certainty of an accelerated approval for the company's gene therapy for a muscle-wasting genetic disorder.
Read more »

Brain-based treatment for menopausal hot flushes approved by FDABrain-based treatment for menopausal hot flushes approved by FDAInvestigations into the impact of menopause on the brain have yielded a new way to treat troublesome symptoms without hormones.
Read more »



Render Time: 2025-02-27 09:27:40